


SUPPLEMENTARY DATA

Supplementary Figure 1. *In vitro* optimal pretreatment condition for cell therapy. (a) Dose-related effects (n=15 per group) and (b) time-related effects (n=5) of ephrin-B2/Fc treatment on the *in vitro* adhesion ability of PB-MNC from health donors. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.



Supplementary Figure 2. Detection of human DNA in muscle, liver, spleen, heart and lung of non-diabetic mice receiving 10^5 PB-MNC from diabetics (n=12).

